RFG Advisory LLC Invests $532,000 in Exelixis, Inc. $EXEL

RFG Advisory LLC purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 12,407 shares of the biotechnology company’s stock, valued at approximately $532,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Fifth Third Wealth Advisors LLC boosted its holdings in Exelixis by 3.8% in the first quarter. Fifth Third Wealth Advisors LLC now owns 9,077 shares of the biotechnology company’s stock worth $389,000 after purchasing an additional 333 shares in the last quarter. OP Asset Management Ltd acquired a new stake in shares of Exelixis in the first quarter worth about $456,000. Banque Cantonale Vaudoise acquired a new stake in shares of Exelixis in the first quarter worth about $249,000. Brookstone Capital Management boosted its stake in shares of Exelixis by 31.6% during the 1st quarter. Brookstone Capital Management now owns 21,158 shares of the biotechnology company’s stock worth $907,000 after acquiring an additional 5,076 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Exelixis by 39.2% during the 1st quarter. SG Americas Securities LLC now owns 50,495 shares of the biotechnology company’s stock worth $2,166,000 after acquiring an additional 14,207 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insider Activity at Exelixis

In other news, Director George Poste sold 60,000 shares of the firm’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $45.71, for a total value of $2,742,600.00. Following the sale, the director owned 118,832 shares in the company, valued at approximately $5,431,810.72. This trade represents a 33.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Patrick J. Haley sold 32,110 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $49.81, for a total transaction of $1,599,399.10. Following the transaction, the executive vice president directly owned 357,638 shares in the company, valued at $17,813,948.78. This trade represents a 8.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 219,170 shares of company stock valued at $10,620,641. 2.60% of the stock is owned by corporate insiders.

Exelixis Stock Performance

Exelixis stock opened at $54.28 on Tuesday. Exelixis, Inc. has a 52 week low of $33.76 and a 52 week high of $55.91. The firm has a market capitalization of $13.64 billion, a PE ratio of 18.03, a PEG ratio of 1.58 and a beta of 0.41. The business’s 50-day simple moving average is $49.78 and its 200-day simple moving average is $45.61.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.12. The firm had revenue of $610.81 million during the quarter, compared to the consensus estimate of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.55 EPS. Research analysts forecast that Exelixis, Inc. will post 3.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

EXEL has been the topic of a number of recent analyst reports. Royal Bank Of Canada cut their price objective on Exelixis from $46.00 to $43.00 and set a “sector perform” rating on the stock in a research note on Monday, March 2nd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Exelixis in a research report on Tuesday, May 19th. Barclays increased their price target on Exelixis from $44.00 to $45.00 and gave the company an “equal weight” rating in a report on Monday, April 20th. Citizens Jmp lifted their price target on shares of Exelixis from $50.00 to $55.00 and gave the company a “market outperform” rating in a research report on Wednesday, June 24th. Finally, Wall Street Zen upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Exelixis presently has a consensus rating of “Hold” and a consensus price target of $46.87.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.